No. 18-1280

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Petition DENIED.

Reply of petitioner Acorda Therapeutics, Inc. filed.

Brief of respondents Mylan Pharmaceuticals Inc., et al. in opposition filed.

Brief amicus curiae of Biotechnology Innovation Organization filed.

Brief amici curiae of Allergan, Inc., et al. filed.

Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.

Brief amicus curiae of Intellectual Property Owners Association in support of neither party filed.

Motion to extend the time to file a response is granted and the time is extended to and including June 7, 2019, for all respondents.

Motion to extend the time to file a response from May 8, 2019 to June 7, 2019, submitted to The Clerk.

Petition for a writ of certiorari filed. (Response due May 8, 2019)


Acorda Therapeutics, Inc., Petitioner, represented by Theodore B. Olson

Mylan Pharmaceuticals Inc., Respondent, represented by Dan L. Bagatell

Roxane Laboratories, Inc., and Teva Pharmaceuticals USA, Inc., Respondent, represented by Charles Bennett Klein

Amici Curiae

Allergan, Inc., Helsinn Healthcare S.A., Breas Medical AB, Akebia Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., Amicus Curiae, represented by Sarah Michelle Harris

Biotechnology Innovation Organization, Amicus Curiae, represented by Charles Edmund Lipsey

Boston Patent Law Association, Amicus Curiae, represented by Sophie Feifei Wang

INTELLECTUAL PROPERTY OWNERS ASSOCIATION, Amicus Curiae, represented by Paul H. Berghoff

Pharmaceutical Research and Manufacturers of America, Amicus Curiae, represented by Beth Susan Brinkmann

Last updated: May 28, 2024